SCHEMBL30007092

SCHEMBL30007092

COc1cc(C(N)=O)cc2cc(C)cnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.48
TSHR P16473 2/20 0.44
HTT P42858 2/20 0.44
APOBEC3A P31941 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
HPGDS O60760 2/20 0.43
BPTF Q12830 1/20 0.43
MAPK1 P28482 1/20 0.42
NNMT P40261 2/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23195851 0.87 CNR2 (0.49) PARP1TSHRHTTHPGDSCCR1
SCHEMBL23905404 0.85 ATM (0.47) PARP1TSHRHTTHPGDSALDH1A1
SCHEMBL30211305 0.82 PARP1 (0.43) PARP1TSHRHTTCCR1CCR5
SCHEMBL23905400 0.82 HSD17B2 (0.49) TSHRHTTHPGDSSMN1; SMN2NPC1
SCHEMBL30339881 0.81 SMN1; SMN2 (0.44) PARP1TSHRHTTAPOBEC3AAPOBEC3G
SCHEMBL30007169 0.81 TSHR (0.45) TSHRHTTAPOBEC3AAPOBEC3GHPGDS
SCHEMBL23904743 0.79 CCR1 (0.52) PARP1HPGDSALDH1A1CCR1CCR5
SCHEMBL23958866 0.78 KMT2A (0.51) HPGDSALDH1A1KDM4ENPC1MAPT
SCHEMBL30211275 0.77 MAPT (0.53) PARP1HTTHPGDSMAPK1ALDH1A1
SCHEMBL30007781 0.75 TSHR (0.43) TSHRHTTAPOBEC3AAPOBEC3GHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2023052593-A1 RSV INHIBITING SPIRO BEARING DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2023-04-06 WO disclosed
EP-4139293-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2023-03-01 EP disclosed
CN-115461336-A RSV inhibiting 3-substituted quinoline and cinnoline derivatives 爱尔兰詹森科学公司 2022-12-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE PARP1 683/4885TSHR 4595/4885HTT 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.